ArticleCancer medicine2026
A Novel Nomogram Incorporating the Aggregate Index of Systemic Inflammation, Clinicopathological Parameters and Molecular Classification to Predict Recurrence of Endometrial Cancer: A Multi-Center Retrospective Study.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
This study evaluated the aggregate index of systemic inflammation (AISI) for predicting postoperative recurrence in endometrial cancer (EC). A total of 1557 patients were enrolled and divided into training (n = 1030) and validation (n = 527) cohorts. The optimal AISI cutoff was determined by ROC curve analysis. Multivariate Cox regression identified eight independent prognostic factors for recurrence-free survival (all p < 0.05): age ≥ 60 (HR = 1.683, 95% CI 1.191-2.377), FIGO stage III (HR = 2.346, 95% CI 1.480-3.718), LVSI (HR = 1.792, 95% CI 1.226-2.618), CA125 ≥ 35 U/mL (HR = 1.457, 95% CI 1.030-2.062), deep myometrial invasion (HR = 2.021, 95% CI 1.393-2.930), histological type II (HR = 1.798, 95% CI 1.219-2.653), p53 abnormal (HR = 3.252, 95% CI 2.142-4.936), and high AISI (HR = 2.492, 95% CI 1.714-3.625). A prognostic nomogram incorporating these factors was constructed and validated, demonstrating superior predictive accuracy compared to conventional methods. Adjuvant therapy significantly improved outcomes in high-risk patients identified by the nomogram. This comprehensive tool enhances risk stratification and may guide personalized treatment planning.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.